On October 13, 2023, Nanjing Zenshine Pharmaceuticals Co., Ltd. closed the transaction. The company has raised over CNY 100 million in the transaction. The transaction included participation from Hubei Jumpcan Pharmaceutical Co., Ltd. for 3.40520% stake for CNY 60 million, Kunlun Capital, Zhejiang Saizhi Bole Equity Investment Management Co., Ltd, Zhongshan Zhonghui Investment Group Co.,ltd.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
41.63 CNY | -1.49% | +1.19% | +32.45% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+32.45% | 5.31B | |
+30.38% | 684B | |
+26.51% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.70% | 240B | |
+8.78% | 208B | |
-7.93% | 200B | |
+7.68% | 166B |
- Stock Market
- Equities
- 600566 Stock
- News Hubei Jumpcan Pharmaceutical Co., Ltd.
- Nanjing Zenshine Pharmaceuticals Co., Ltd. announced that it has received CNY 100 million in funding from Hubei Jumpcan Pharmaceutical Co., Ltd., Kunlun Capital, Zhejiang Saizhi Bole Equity Investment Management Co., Ltd, Zhongshan Zhonghui Investment Group Co.,ltd.